{"organizations": [], "uuid": "a5a30ebdc156ad6791f1612bc4c0a3f2db22b9ba", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/02/globe-newswire-obseva-sa-to-hold-fourth-quarter-and-year-end-2017-financial-results-and-business-update-call-on-march-9-2018.html", "country": "US", "domain_rank": 767, "title": "ObsEva SA to Hold Fourth Quarter and Year-end Financial and Business Update Call on March 9, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.013, "site_type": "news", "published": "2018-03-02T15:01:00.000+02:00", "replies_count": 0, "uuid": "a5a30ebdc156ad6791f1612bc4c0a3f2db22b9ba"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/02/globe-newswire-obseva-sa-to-hold-fourth-quarter-and-year-end-2017-financial-results-and-business-update-call-on-march-9-2018.html", "ord_in_thread": 0, "title": "ObsEva SA to Hold Fourth Quarter and Year-end Financial and Business Update Call on March 9, 2018", "locations": [], "entities": {"persons": [{"name": "obseva obseva", "sentiment": "none"}], "locations": [{"name": "geneva", "sentiment": "none"}, {"name": "switzerland", "sentiment": "none"}, {"name": "boston", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "obseva sa", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Geneva, Switzerland and Boston, MA - March 2, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will release fourth quarter and year-end 2017 financial results the morning of Friday, March 9, 2018. ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, on March 9, 2018, to discuss these financial results and provide a corporate update.\nInvestors may participate by dialing (844) 419-1772 for U.S. callers and (213) 660-0921 for international callers, and referring to conference ID 9062388. A webcast of the conference call can be accessed under the \"Investors\" section of ObsEva's website www.obseva.com .\nAbout ObsEva\nObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol \"OBSV\". For more information, please visit www.ObsEva.com .\n###\nMedia Contact:\nLiz Bryan\nSpectrum Science\nlbryan@spectrumscience.com\n202-955-6222 x2526\nCompany Contact:\nCEO Office contact\nShauna Dillon\nShauna.dillon@obseva.ch\n+41 22 552 1550\nInvestor Contact\nMario Corso\nSenior Director, Investor Relations\nmario.corso@obseva.com\nOffice 857-972-9347\nMobile 781-366-5726\nAttachment:\nhttp://www.globenewswire.com/NewsRoom/AttachmentNg/6921e946-868b-4433-b3ef-17e440e4dad2\nSource:ObsEva SA", "external_links": ["https://www.globenewswire.com/Tracker?data=NTmYcqYBeP5pGa-Tx62RSc1Nk8ipAb0Ap4C_pDyXGYhXM3a1zlptBF1F6cJOB27sh1C3Ri5zMTdWHT-Vo389XYePSFehErck0ZchWsdWNEo=", "https://www.globenewswire.com/Tracker?data=1OhmLrS3Lrtkgq3nGTeL0XweABR22gMGUK47dOxrNOaNxHmtwiH4bov0YY9Hu6akOa2-zg6nJOllYEQ7txod7A==", "https://www.globenewswire.com/Tracker?data=FxvAfKU978oajMJh1Z_QYWJ3xSEBDOOOj41aZmW9Qz8SHr7NlkIpZU363yz9xZsb1NyIrrsogybY_gK4xB-jQcDqMbQ3cyADAuRM-VC8u82rXFYeL-duolo9pCZKvQu9", "https://www.globenewswire.com/Tracker?data=IDYwajiJz9C7g-yExDTbMMl3OlkCBhxf0V3q9lX2hRXBp_JpWfZyDjlQtsqubJ3LB5uEw_kGxUbLO3w-q8ak6w==", "https://www.globenewswire.com/Tracker?data=gfAQ-5oAAYW8H0qQrgd_dY_PgNhdtJLOFeZGMpeIVEgxSFcX0y3m-jX3-UaMIgFFl6UvLEvItWW77vdFMk9rzLbPK82elgtOp0S398GKmaJwZN8QfwusgtnKVULs8NjY1T9khZYnrw8EjAqkztsCen9RDzKCk4ZesXGWOsqVV8uogpCpRoxWU1eiQ5eP5d8gL9bpVrsk-sGurtYsH8vtrBGJ-PKHUIvHCw-qXMbQGDKWNdef_6QmbZdvzp8xf-uhYHpohTjrnPwq1K4S8Tzlqg==", "http://www.globenewswire.com/NewsRoom/AttachmentNg/6921e946-868b-4433-b3ef-17e440e4dad2", "https://www.globenewswire.com/NewsRoom/AttachmentNg/390cf3d9-f493-43bf-8d14-d2c6ebfc132b", "https://www.globenewswire.com/Tracker?data=B1wqJyzoaCKzbTasCmbVFGpOCduXQW36VCqseorAAusc_b4HxLX_xMwYwhJfN7WRrwYqbN8M6WgkCZ7vzPo9jXvFE5QmwNfzPj5MqRUvTII="], "published": "2018-03-02T15:01:00.000+02:00", "crawled": "2018-03-02T15:16:49.007+02:00", "highlightTitle": ""}